drugset / Trial / NCT00829530

Ramipril 10 mg Capsule in Healthy Subjects Under Fed Conditions

NCT00829530

Phase 1 Completed 40 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study is to compare the rate and extent of absorption of Ramipril 10 mg capsule (test) versus Altace® (reference), administered as 1 x 10 mg capsule under fed conditions.

Timeline

Start
2004-08
Primary completion
2004-10
Completion
2004-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ramipril Small molecule 10 mg

Indications

No indication recorded.